← Back to Search

NHL for Chronic Lymphocytic Leukemia

N/A
Waitlist Available
Research Sponsored by Adaptive Biotechnologies
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 yrs
Awards & highlights

Summary

This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.

Eligible Conditions
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin's Lymphoma
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 yrs
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 yrs for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Malignant Neoplasms
Secondary study objectives
Numbers of lymphoid malignancy patients with de-intensifications to their drug regimens based upon clonoSEQ MRD results
Numbers of lymphoid malignancy patients with intensifications to their drug regimens based upon clonoSEQ MRD results
Other study objectives
Average numbers of clonoSEQ Assay orders placed for enrolled lymphoid malignancy patients in routine clinical practice relative to other response assessments
Differences in outcomes between clonoSEQ Assay MRD-negative and MRD-positive lymphoid malignancy patients

Trial Design

4Treatment groups
Experimental Treatment
Group I: NHLExperimental Treatment1 Intervention
patients diagnosed with non-Hodgkin lymphoma
Group II: MMExperimental Treatment1 Intervention
patients diagnosed with multiple myeloma
Group III: CLLExperimental Treatment1 Intervention
patients diagnosed with chronic lymphocytic leukemia
Group IV: ALLExperimental Treatment1 Intervention
patients diagnosed with acute lymphoblastic leukemia

Find a Location

Who is running the clinical trial?

Adaptive BiotechnologiesLead Sponsor
12 Previous Clinical Trials
3,172 Total Patients Enrolled
John Pagel, MD, PhDStudy ChairSwedish Cancer Institute
2 Previous Clinical Trials
120 Total Patients Enrolled
Heidi Simmons, PhDStudy DirectorAdaptive Biotechnologies
1 Previous Clinical Trials
300 Total Patients Enrolled
~95 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top